Medicine Technology
Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
| 12/1/2008 | Baby Girl with Hypophosphatasia Treated With ENB-0040 at Children's Hospital, Health Sciences Centre in Winnipeg MONTREAL, Dec. 1 Enobia Pharma, an emerging Canadian biotech company focused on developing novel therapeutics for serious bone disorders, today announced that the first infant patient in its clinical program for hypophosphatasia was dosed. Enobia is investig... [Comments] |
Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity
| 12/1/2008 | St. Jude study shows the Prox1 gene is a two-way switch that, if turned off, causes lymphatic endothelial cells to be reprogrammed so that they lose their identity and become more like blood endothelial cells MEMPHIS, Tenn., Dec. 1 Scientists at St. Jude Children's Research Hospital have discovered that a certain differentiated cell type is so ready to chan... [Comments] |
Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis
| 12/1/2008 | Abstinence is still the best policy ROCHESTER, Minn., Dec. 1 A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology ( http://ww... [Comments] |
Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
| 12/1/2008 | PLYMOUTH MEETING, Pa., Dec. 1 Genaera Corporation (Nasdaq: GENR ) today announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which works centrally a... [Comments] |
| 12/1/2008 | KVISTGARD, Denmark, December 1 Following aRequest for Proposal issued in 2007 with the intent to procure an MVA-based,third generation smallpox vaccine, Public Works and Government ServicesCanada, on behalf of the Canadian Department of National Defence, has awardeda contract to Bavarian Nordic for the delivery of IMVAMUNE(R). The Canadian authoriti... [Comments] |
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
| 12/1/2008 | -- Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML -- SOUTH SAN FRANCISCO, Calif., Dec. 1 Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced new data from its studies of voreloxin... [Comments] |
GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
| 12/1/2008 | ATLANTA, Dec. 1 GeoVax Labs, Inc.(OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company developinghuman vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) andother infectious agents, announced today that the launch of its Phase 2a HumanVaccine Trials will take place in twelve sites across North and South America.These trials are c... [Comments] |
| 12/1/2008 | SAN DIEGO, Dec. 1 Vical Incorporated (Nasdaq: VICL ) announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The candidate vaccine is based on Vical's DNA gene delivery technology and encodes human telomerase rever... [Comments] |
Exercise Helps Prevent Age-Related Brain Changes in Older Adults
| 11/30/2008 | CHICAGO, Dec. 1 Older adults who exercise regularly show increased cerebral blood flow and a greater number of small blood vessels in the brain, according to findings presented today at the annual meeting of the Radiological Society of North America (RSNA). The study, conducted at the University of North Carolina ( UNC) - Chapel Hill , is the... [Comments] |
Brain Waves Show Sound Processing Abnormalities in Autistic Children
| 11/30/2008 | CHICAGO, Dec. 1 Abnormalities in auditory and language processing may be evaluated in children with autism spectrum disorder by using magnetoencephalography (MEG), according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA). "Using MEG, we can record the tiny magnetic fields associated with electrical brain... [Comments] |
(Date:12/1/2008)...ecent release of data from the National Oncologic ...the moment of critical mass by confirming the effe... the monitoring of tumor activity across a wide ra...study, we verified that PET finds more areas of ac... some cases, to earlier initiation of subsequent t...
(Date:12/1/2008)...rthopaedic surgeon is the driving force for a safe... Dec. 1 /PRNewswire-USNewswire/ - - While many pa...musculoskeletal injury may be anxious to get back ... get behind the wheel of a car can be a difficult ...concerns of orthopaedic surgeons and patients alik...
(Date:12/1/2008)...RNewswire/ -- Sciton introduces ProLipo,PLUS(TM),...wered laser system,for ablating and melting unwan...sue tightening. ProLipo PLUS combines 1064 nm and...y sculpting results. Frequently used as an adjunc...ized as a standalone procedure,for patients who a...
(Date:12/1/2008)... An independent study at the,Univ...ngsters want to play,video games at the same time...xercise. , Fifty children aged 11 and 12 we...video games provided by a company called Gamercize...y while they maintained movement on,the fitness m...
Breaking Medicine News(10 mins):Health News:Nationwide study confirms PET as the most powerful imaging tool in cancer management 2Health News:When to Get Back Behind the Wheel While on the Road to Recovery 2Health News:When to Get Back Behind the Wheel While on the Road to Recovery 3Health News:Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available 2Health News:Children Tell Researchers: We'll Get Fit if It's Fun 2[0] Nationwide study confirms PET as the most powerful imaging tool in cancer management[0] When to Get Back Behind the Wheel While on the Road to Recovery[0] Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available[0] Children Tell Researchers: We'll Get Fit if It's Fun
...esearchers have found the mechanism through which ...comparatively good health and vigour, free of deg...acid has been found to slow down the process of ag...enhance immune function, and perform many other fu...
...t intake of cruciferous vegetables with a high con...efit against bladder cancer. Isothiocyanates (... such as broccoli, cauliflower, kale, turnips, col..., cabbage, radish, turnip and watercress. They ap...
...hyperactive behaviour and poor academic achievemen...influences. Although the relationship between suc...attentiveness in children and poor achievement in ...areas has been well documented, little is known ab...
... addition of folic acid to flour or bread mandator...h severe disabilities. After lengthy public cons... that it would approach the Government with its re...r it decides whether folic acid should be added to...
Other Medicine News:Health News:Lipoic Acid may Help to Live Long, Free of Degenerative Disease 2Health News:Risk of Bladder Cancer Reduced by Broccoli and Cauliflower 2Health News:UK too Will Insist on Folic Acid in Bread 2Health News:UK too Will Insist on Folic Acid in Bread 3The KY is a low profile implantable bipolar fixed screw-in permanent pacing lead for stimulation of either the atrium or the ventricle. The KY lead is supplied with a screwdriver shape stylet which i
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics.
Implantable medical grade silicone sleeve for adapting a 5 mm (01) connector to a 6 mm (02) connector.
...e only ICD system in the world for biatrial stimul... of interatrial connection blockages. The patients...ynamics and long term protection against cardiac r...ffectively suppress the typical symptomatic and me...
Medicine Products:(Date:11/24/2008)...TO, Nov. 24 /PRNewswire-FirstCall/ - Predictive me...ay announced that it has entered into a fully fund...rld,s largest cosmetic companies. PreMD,s PREVU* s...ith one of the cosmetic company,s skin care produc...arlier successful study completed by PreMD with th...
(Date:11/24/2008)...ASHINGTON, Nov. 24 , ...st four year Presidential term will start with bil.... As spokesman for the Repair Stem Cell,Institut...ll research and,treatment industry worldwide, I w...support for our industry and the medical and scien...
(Date:11/24/2008)...OPHIA ANTIPOLIS, France, November 24 /PRNewswire-F...) today announced that the third pivotal phase,3 ...ip showed a highly,statistically significant resu...endpoints of the trial. Naproxcinod 750 mg bid sho...rate and a similar blood pressure profile,to plac...
(Date:11/23/2008)...ILLE, Tenn., Nov. 24 A new cancer ...t pancreatic cancer. Following five weeks,of trea...d in size by 70%.,After seven more weeks of treat... on scans. Pancreatic cancer usually is fatal six ...n,s combination of FDA-approved drugs,appears to ...
Breaking Medicine Technology:PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate 2Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute 2Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 2Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 3Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 4Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results 5New Cancer Treatment Shrinks Pancreatic Tumor 2 26quot 3BBrave New Reality 26quot 3B Provides a Wide Spectrum of High Tech News and Easy Science 6320 1 26quot 3BBrave New Reality 26quot 3B Provides a Wide Spectrum of High Tech News and Easy Science 6320 2 26quot 3BBrave New Reality 26quot 3B Provides a Wide Spectrum of High Tech News and Easy Science 6320 3Release of Kowalski Book on Attaining Healthy Blood Pressure Coincides with Website Launch New Endurance Products SR L Arginine and Grape Seed Extrac 22994 1Release of Kowalski Book on Attaining Healthy Blood Pressure Coincides with Website Launch New Endurance Products SR L Arginine and Grape Seed Extrac 22994 2Release of Kowalski Book on Attaining Healthy Blood Pressure Coincides with Website Launch New Endurance Products SR L Arginine and Grape Seed Extrac 22994 3Flaws in the barcoded technology used to reduce medication administration errors identified 22991 1Flaws in the barcoded technology used to reduce medication administration errors identified 22991 2Flaws in the barcoded technology used to reduce medication administration errors identified 22991 3Flaws in the barcoded technology used to reduce medication administration errors identified 22991 4Violence declines with medication use in some with schizophrenia 22987 1Violence declines with medication use in some with schizophrenia 22987 2[0] PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate[0] Open Letter to President-Elect Barack Obama From Don Margolis, Chairman and Founder of The Repair Stem Cell Institute[1] Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results[0] New Cancer Treatment Shrinks Pancreatic Tumor
...nd Other Human,Papillomavirus Related Diseases Aft...III Clinical Studies Which Included More Than,17,0...hes the most comprehensive,and robust clinical dat...nce, 10th May2007 – New clinical study resul...asil® in the,prevention of cervical cancer and...
...tisense,Pharma today announced, that the abstract ...I-Study in Pancreatic,Carcinoma, Malignant Melanom...ibitor AP 12009” has been selected for poste...merican Society of,Clinical Oncology (ASCO), which...ne 1st - 5th. , In the Phase I/II-trial the antise...
Other Medicine Technology:Gardasil Demonstrates Up to 100% Efficacy 2Gardasil Demonstrates Up to 100% Efficacy 3Gardasil Demonstrates Up to 100% Efficacy 4Gardasil Demonstrates Up to 100% Efficacy 5Gardasil Demonstrates Up to 100% Efficacy 6Gardasil Demonstrates Up to 100% Efficacy 7Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor,AP 12009 to be Presented 2| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |